Terms: = Head and neck cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Prognosis
115 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Genetic alterations and allele frequency of BRAF V600E and tert mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.
Huang J; Wang J; Xv J; Wang J; Wang G; Zhao Y
Clin Exp Med; 2024 Apr; 24(1):76. PubMed ID: 38607456
[TBL] [Abstract] [Full Text] [Related]
3. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.
Ghossein R; Katabi N; Dogan S; Shaha AR; Tuttle RM; Fagin JA; Ganly I; Xu B
Histopathology; 2024 Jun; 84(7):1130-1138. PubMed ID: 38528726
[TBL] [Abstract] [Full Text] [Related]
4. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
5. Clinical and molecular features of progressive papillary thyroid microcarcinoma.
Wang Z; Ji X; Zhang H; Sun W
Int J Surg; 2024 Apr; 110(4):2313-2322. PubMed ID: 38241301
[TBL] [Abstract] [Full Text] [Related]
6. Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and prognosis Based on WHO Classification and tert Promoter Mutation.
Kim MK; Park H; Oh YL; Shin JH; Kim TH; Hahn SY
Korean J Radiol; 2024 Jan; 25(1):103-112. PubMed ID: 38184773
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of integrated hepatitis B virus DNA harboring pre-S mutations in hepatocellular carcinoma patients with ground glass hepatocytes.
Su YP; Lin SY; Su IJ; Kao YL; Shen SC; Earl JP; Ehrlich GD; Chen CY; Huang W; Su YH; Tsai HW
J Med Virol; 2024 Jan; 96(1):e29348. PubMed ID: 38180275
[TBL] [Abstract] [Full Text] [Related]
8. Gene mutations as predictors of central lymph mode metastasis in cN0 PTC: A meta-analysis.
Ji J; Shi X
Clin Genet; 2024 Feb; 105(2):130-139. PubMed ID: 37985961
[TBL] [Abstract] [Full Text] [Related]
9. Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: Systematic review.
de Sousa MSA; Nunes IN; Christiano YP; Sisdelli L; Cerutti JM
Rev Endocr Metab Disord; 2024 Feb; 25(1):35-51. PubMed ID: 37874477
[TBL] [Abstract] [Full Text] [Related]
10. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract] [Full Text] [Related]
11. Copy-number-gain of telomerase reverse transcriptase (htert) is associated with an unfavorable prognosis in esophageal adenocarcinoma.
Lyu SI; Popp FC; Simon AG; Schultheis AM; Zander T; Fretter C; Schröder W; Bruns CJ; Schmidt T; Quaas A; Knipper K
Sci Rep; 2023 Oct; 13(1):17699. PubMed ID: 37848472
[TBL] [Abstract] [Full Text] [Related]
12. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and tert promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
13. DICER1 Mutations Do Not Always Indicate Dismal prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
[TBL] [Abstract] [Full Text] [Related]
14. tert promoter mutations in thyroid cancer.
Matsuse M; Mitsutake N
Endocr J; 2023 Nov; 70(11):1035-1049. PubMed ID: 37532521
[TBL] [Abstract] [Full Text] [Related]
15. Incidence and Clinicopathological Features of Differentiated High-Grade Thyroid Carcinomas: An Institutional Experience.
Jeong SI; Kim W; Yu HW; Choi JY; Ahn CH; Moon JH; Choi SI; Cha W; Jeong WJ; Park SY; Na HY
Endocr Pathol; 2023 Sep; 34(3):287-297. PubMed ID: 37515661
[TBL] [Abstract] [Full Text] [Related]
16. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract] [Full Text] [Related]
17. Predictive factors for nodal recurrence in differentiated thyroid cancers.
Kaur J; Nadarajan A; Janardhan D; George NA; Thomas S; Varghese BT; Krishna J
Cancer Treat Res Commun; 2023; 36():100728. PubMed ID: 37336036
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
[TBL] [Abstract] [Full Text] [Related]
19. Genetic Considerations in the Tumorigenesis, Diagnosis, and Treatment of Differentiated Thyroid cancer: Current State of the Science.
Richmond BK; Gallimore J
Am Surg; 2023 Nov; 89(11):4853-4859. PubMed ID: 37253623
[TBL] [Abstract] [Full Text] [Related]
20. Budding uninhibited by benzimidazoles 1 might be a poor prognosis biomarker promoting the progression of papillary thyroid cancer.
Jiang W; Yu Y; Bhandari A; Hirachan S; Dong X; Huang X; Qu J; Chen C
Environ Toxicol; 2023 Sep; 38(9):2047-2056. PubMed ID: 37163344
[TBL] [Abstract] [Full Text] [Related]
[Next]
